Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990, SHE:002422) partner Windward Bio reported positive interim results from phase 2 of the POLARIS-1 clinical trial of SKB378/WIN378.
The drug targets thymic stromal lymphopoietin in asthma, according to a Tuesday Hong Kong bourse filing.
According to the results, the drug was well tolerated, with favorable safety results and no treatment-related serious adverse events, withdrawals, or discontinuations.
Phase 3 of the trial has commenced.
Majestic Dragon Aerotech (HKG:0918) has appointed Zhang Chen as the company's chief marketing officer, according to a Monday bourse filing.Zhang has over 10 years of experience in real estate development and in managing hotel operations and fire safety systems. His appointment will be effective Dec. 7.
HRnetGroup (SGX:CHZ) has received in-principle approval from the Singapore Exchange Securities Trading (SGX-ST) for the listing and quotation of 241,527 shares to be transferred to certain employees and executive director.The approval is subject to the company complying with SGX-ST listing requirements, including obtaining specific shareholders' approval where applicable, according to a Monday Singapore Exchange filing.The company will make the necessary announcement once the shares are transferred.
Sequoia Financial Group (ASX:SEQ) former Chief Executive Garry Crole has been banned by the Australian Securities and Investments Commission (ASIC) for 10 years from performing any function involved in carrying on a financial services business as a director or responsible manager, according to a Tuesday statement by ASIC.The regulator said Crole failed to adequately respond to serious concerns about the financial advice model used by former Interprac-authorized representatives, who advised thousands of clients to invest superannuation in the now-collapsed First Guardian and Shield Master Funds.The company did not immediately respond to anemail request for comment.